The largest identified kindred worldwide with a single mutation causing autosomal-dominant Alzheimer’s disease (ADAD) is a family from Antioquia, Colombia, carrying the Presenilin-1 (PSEN1) E280A (Paisa) mutation. The majority of mutation carriers develop dementia, typically commencing in their late 30 s, with a median onset age of 49 years. Cognitive decline is a hallmark feature.
Objective:
This review synthesizes the existing literature on neuropsychological assessments in PSEN1 E280A mutation carriers throughout their lifespan. We provide a comprehensive overview of cognitive outcomes in this unique population.
Methods:
We reviewed and integrated the published research, analyzing studies on neuropsychological assessments in PSEN1 E280A carriers. Our focus was on measures of verbal, semantic, episodic, and spatial memory, and encompassed other cognitive domains such as language, attention, visuospatial memory, and executive functioning.
Results:
Verbal, semantic, episodic, and spatial memory emerged as the most sensitive indicators of preclinical changes in PSEN1 E280A carriers. Inconsistencies were noted in findings from tests assessing language, attention, visuospatial memory, and executive functioning, suggesting potential limitations in detecting early cognitive changes in PSEN1 mutation carriers. Specific cognitive tasks developed for this population proved effective but underutilized.
Conclusions:
The review underscores the importance of continued test development tailored to detect early cognitive changes in PSEN1 E280A carriers, potentially enhancing ADAD screening. Furthermore, investigating ADAD mutations in children may identify early changes in AD and enhance our understanding of neuropsychological functioning across the lifespan. This synthesis provides valuable insights for researchers, clinicians, and policymakers engaged in the study and management of ADAD.
2020 Alzheimer’s disease facts and figures. Alzheimers Dement2020; 16: 391–460.
2.
Corey-BloomJ. The ABC of Alzheimer’s disease: cognitive changes and their management in Alzheimer’s disease and related dementias. Int Psychogeriatr2002; 14(Suppl 1): 51–75.
3.
MurmanDL. The impact of age on cognition. Semin Hear2015; 36: 111–121.
4.
SchindlerSE, FaganAM. Autosomal dominant Alzheimer disease: a unique resource to study CSF biomarker changes in preclinical AD. Front Neurol2015; 6: 142.
BatemanRJ, AisenPS, De Strooper B, et al.. Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther2010; 3: 1.
7.
LoperaF, MadrigalL, KosikKS, et al.. Demencia tipo Alzheimer con agregación familiar en Antioquia, Colombia. Acta Neurol Colomb1994; 10: 173–187.
8.
QuirozYT, SchultzA, ChenK, et al.. Brain imaging and blood biomarker abnormalities in children with autosomal-dominant Alzheimer’s disease: A cross-sectional Study. JAMA Neurol2015; 72: 912–919.
9.
Acosta-BaenaN, Sepulveda-FallaD, Lopera-GómezCM, et al.. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer’s disease: a retrospective cohort study. Lancet Neurol2011; 10: 213–220.
10.
Fox-FullerJT, ArtolaA, ChenK, et al.. Sex differences in cognitive abilities among children with the autosomal dominant Alzheimer disease presenilin 1 E280A variant from a Colombian cohort. JAMA Netw Open2021; 4: e2121697.
11.
BobesMA, GarcíaYF, LoperaF, et al.. ERP generator anomalies in presymptomatic carriers of the Alzheimer’s disease E280A PS-1 mutation. Hum Brain Mapp2010; 31: 247–265.
12.
Guzmán-VélezE, ZetterbergH, Fox-FullerJT, et al.. Associations between plasma neurofilament light, in vivo brain pathology and cognition in non-demented individuals with autosomal- dominant Alzheimer’s disease. Alzheimers Dement2021; 17: 813–821.
13.
WechslerD. Wechsler Intelligence Scale for Children. 4th, Spani ed. San Antonio: The Psychological Corporation; 2005.
14.
WechslerD, Padilla SierraG. WISC-IV: escala Wechsler de inteligencia para niños-IV. México, D.F.: EL Manual Moderno; 2007.
15.
LoperaF, MarinoC, ChandrahasAS, et al.. Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man. Nat Med2023; 29: 1243–1252.
16.
Arboleda-VelasquezJF, LoperaF, O’HareM, et al.. Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat Med2019; 25: 1680–1683.
17.
FullerJT, Cronin-GolombA, GatchelJR, et al.. Biological and cognitive markers of presenilin1 E280A autosomal dominant Alzheimer’s disease: a comprehensive review of the Colombian kindred. J Prev Alzheimers Dis2019; 6: 112–120.
18.
MorrisJC, HeymanA, MohsRC, et al.. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology1989; 39: 1159–1165.
19.
WelshKA, ButtersN, MohsRC, et al.. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology1994; 44: 609–614.
20.
Aguirre-AcevedoDC, GómezRD, MorenoS, et al.. Validez y fiabilidad de la batería neuropsicológica CERAD-Col. Rev Neurol Ed Impr2007)655–660.
21.
Aguirre-AcevedoDC, LoperaF, HenaoE, et al.. Cognitive decline in a Colombian kindred with autosomal dominant Alzheimer disease: a retrospective cohort study. JAMA Neurol2016; 73: 431–438.
22.
BaenaA, BocanegraY, TorresV, et al.. Neuroticism is associated with tau pathology in cognitively unimpaired individuals with autosomal dominant Alzheimer’s disease. J Alzheimers Dis2021; 82: 1809–1822.
23.
Rios-RomenetsS, LoperaF, SinkKM, et al.. Baseline demographic, clinical, and cognitive characteristics of the Alzheimer’s Prevention Initiative (API) Autosomal-Dominant Alzheimer’s Disease Colombia Trial. Alzheimers Dement2020; 16: 1023–1030.
24.
VanniniP, HanseeuwBJ, GatchelJR, et al.. Trajectory of unawareness of memory decline in individuals with autosomal dominant Alzheimer disease. JAMA Netw Open2020; 3: e2027472.
25.
Vila-CastelarC, PappKV, AmariglioRE, et al.. Validation of the latin American spanish version of the face-name associative memory exam in a colombian sample. Clin Neuropsychol2020; 34(sup1): 1–12.
26.
MartinezJE, DelgadoEP, Guzmán-VélezE, et al.. Subjective cognitive decline and its relation to verbal memory and sex in cognitively unimpaired individuals from a Colombian cohort with autosomal dominant Alzheimer’s disease. J Int Neuropsychol Soc2022; 28: 541–549.
27.
RosselliM, ArdilaA, MorenoS, et al.. Cognitive decline in patients with familial Alzheimer’s disease associated with E280a presenilin-1 mutation: a longitudinal study. J Clin Exp Neuropsychol2000; 22: 483–495.
28.
TiradoV, MottaM, Aguirre-AcevedoDC, et al.. Analysis of intrusive errors in a memory test as possible pre-clinical marker of familial Alzheimer disease, in E280A presenilin-1 mutation carrier. Rev Neurol2008; 47: 290–294.
29.
BuschkeH. Selective reminding for analysis of memory and learning. J Verbal Learn Verbal Behav1973; 12: 543–550.
30.
GroberE, LiptonRB, HallC, et al.. Memory impairment on free and cued selective reminding predicts dementia. Neurology2000; 54: 827–832.
31.
YucebasD, Fox-FullerJT, CabreraAB, et al.. Associations of category fluency clustering performance with in vivo brain pathology in autosomal dominant Alzheimer’s disease. J Int Neuropsychol Soc2024; 30: 77–83.
32.
Vila-CastelarC, TariotPN, SinkKM, et al.. Sex differences in cognitive resilience in preclinical autosomal-dominant Alzheimer’s disease carriers and non-carriers: Baseline findings from the API ADAD Colombia Trial. Alzheimers Dement2022; 18: 2272–2282.
33.
Arango-LasprillaJC, CuetosF, ValenciaC, et al.. Cognitive changes in the preclinical phase of familial Alzheimer’s disease. J Clin Exp Neuropsychol2007; 29: 892–900.
34.
VogelA, GadeA, StokholmJ, et al.. Semantic memory impairment in the earliest phases of Alzheimer’s disease. Dement Geriatr Cogn Disord2005; 19: 75–81.
35.
Estévez-GonzálezA, García-SánchezC, BoltesA, et al.. Semantic knowledge of famous people in mild cognitive impairment and progression to Alzheimer’s disease. Dement Geriatr Cogn Disord2004; 17: 188–195.
36.
VogelEK, WoodmanGF and LuckSJ. Storage of features, conjunctions and objects in visual working memory. J Exp Psychol Hum Percept Perform2001; 27: 92–114.
37.
TreismanA. Object Tokens, binding and visual memory. In: Zimmer H, Mecklinger A, Lindenberger U (eds) Handbook of Binding and Memory: Perspectives From Cognitive Neuroscience. Oxford University Press, 2006, pp. 315–338.
38.
BrockmoleJR, ParraMA, Della SalaS, et al.. Do binding deficits account for age-related decline in visual working memory?Psychon Bull Rev2008; 15: 543–547.
39.
KopparaA, FrommannI, PolcherA, et al.. Feature binding deficits in subjective cognitive decline and in mild cognitive impairment. J Alzheimers Dis2015; 48(Suppl 1): S161–S170.
40.
ParraMA, AbrahamsS, FabiK, et al.. Short-term memory binding deficits in Alzheimer’s disease. Brain2009; 132: 1057–1066.
41.
ParraMA, SaarimäkiH, BastinME, et al.. Memory binding and white matter integrity in familial Alzheimer’s disease. Brain2015; 138: 1355–1369.
42.
ParraMA, AbrahamsS, LogieRH, et al.. Visual short-term memory binding deficits in familial Alzheimer’s disease. Brain2010; 133: 2702–2713.
43.
NortonDJ, ParraMA, SperlingRA, et al.. Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer’s disease. Alzheimers Res Ther2020; 12: 99.
44.
ReyA and OsterriethPA. Rey-Osterrieth Complex Figure Copying Test. APA PsycTests, 1941.
45.
LoperaF, ArdillaA, MartínezA, et al.. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA1997; 277: 793–799.
46.
BocanegraY, Fox-FullerJT, BaenaA, et al.. Association between visual memory and in vivo amyloid and tau pathology in preclinical autosomal dominant Alzheimer’s disease. J Int Neuropsychol Soc2021; 27: 47–55.
47.
PappKV, AmariglioRE, DekhtyarM, et al.. Development of a psychometrically equivalent short form of the Face-Name Associative Memory Exam for use along the early Alzheimer’s disease trajectory. Clin Neuropsychol2014; 28: 771–785.
48.
RentzDM, AmariglioRE, BeckerJA, et al.. Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia2011; 49: 2776–2783.
49.
Vila-CastelarC, MuñozN, PappKV, et al.. The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer’s disease. Alzheimers Res Ther2020; 12: 104.
50.
García-MagariñoI, Fox-FullerJT, Palacios-NavarroG, et al.. Visual working memory for semantically related objects in healthy adults. Rev Neurol2020; 71: 277–284.
51.
GiffardB. The nature of semantic memory deficits in Alzheimer’s disease: New insights from hyperpriming effects. Brain2001; 124: 1522–1532.
52.
Di GiacomoD, De FedericisLS, PistelliM, et al.. The loss of conceptual associations in mild Alzheimer’s dementia. J Clin Exp Neuropsychol2012; 34: 643–653.
53.
Fox-FullerJT, MartinezJE, BaenaA, et al.. Memory for semantically related objects differentiates cognitively unimpaired autosomal dominant mutation carriers from non-carrier family members. J Prev Alzheimers Dis2023; 10: 322–327.
54.
GiudicessiA, AduenPA, Fox-FullerJT, et al.. The MAPP Room Memory Test: Examining contextual memory using a novel computerized test in cognitively-unimpaired individuals with autosomal dominant Alzheimer’s disease. J Prev Alzheimers Dis2024; 11: 463–468.
55.
GollanTH, WeissbergerGH, RunnqvistE, et al.. Self-ratings of spoken language dominance: A Multi-Lingual Naming Test (MINT) and preliminary norms for young and aging Spanish-English Bilinguals. Biling (Camb Engl)2012; 15: 594–615.
56.
GoodglassH, KaplanE and BarresiB. The Boston Diagnostic Aphasia Examination: BDAE-3 long form kit. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001.
57.
KaplanE, GoodglassH and WeintraubS. Boston naming test. Philadelphia: Lea & Febiger; 1983.
58.
StraussE, ShermanEMS and SpreenO. A compendium of neuropsychological tests: Administration, norms, and commentary, 3rd ed. New York: Oxford University Press; 2006.
59.
ArdilaA, LoperaF, RosselliM, et al.. Neuropsychological profile of a large kindred with familial Alzheimer’s disease caused by the E280A single presenilin-1 mutation. Arch Clin Neuropsychol2000; 15: 515–528.
60.
Guzmán-VélezE, JaimesS, Aguirre-AcevedoDC, et al.. A three-factor structure of cognitive functioning among unimpaired carriers and non-carriers of autosomal-dominant Alzheimer’s disease. J Alzheimers Dis2018; 65: 107–115.
61.
QuirozYT, BudsonAE, CeloneK, et al.. Hippocampal hyperactivation in presymptomatic familial Alzheimer’s disease. Ann Neurol2010; 68: 865–875.
62.
QuirozYT, WillmentKC, CastrillonG, et al.. Successful scene encoding in presymptomatic early-onset Alzheimer’s disease. J Alzheimers Dis2015; 47: 955–964.
63.
FagundoAB, LópezS, RomeroM, et al.. Clustering and switching in semantic fluency: predictors of the development of Alzheimer’s disease. Int J Geriatr Psychiatry2008; 23: 1007–1013.
64.
StasenkoA, JacobsDM, SalmonDP, et al.. The Multilingual Naming Test (MINT) as a measure of picture naming ability in Alzheimer’s disease. J Int Neuropsychol Soc2019; 25: 821–833.
65.
KatsumataY, MathewsM, AbnerEL, et al.. Assessing the discriminant ability, reliability, and comparability of multiple short forms of the Boston Naming Test in an Alzheimer’s disease center cohort. Dement Geriatr Cogn Disord2015; 39: 215–227.
66.
CuetosF, Arango-LasprillaJC, UribeC, et al.. Linguistic changes in verbal expression: a preclinical marker of Alzheimer’s disease. J Int Neuropsychol Soc2007; 13: 433–439.
67.
OrtizSO, OrtizJA and DevineRI. Chapter 12 - Assessment of culturally and linguistically diverse individuals with the Woodcock– Johnson IV. In: Flanagan DP, Alfonso VC (eds) WJ IV Clinical Use and Interpretation. San Diego: Academic Press, pp. 317–353.
Arango LasprillaJC, IglesiasJ, LoperaF. Neuropsychological study of familial Alzheimer’s disease caused by mutation E280A in the presenilin 1 gene. Am J Alzheimers Dis Other Demen2003; 18: 137–146.
70.
RavenJC. Raven’s progressive matrices. Melbourne: Australian Council for Educational Research, 1938.
71.
ReitanRM. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills1958; 8: 271–276.
72.
O’DonnellJP, MacgregorLA, DabrowskiJJ, et al.. Construct validity of neuropsychological tests of conceptual and attentional abilities. J Clin Psychol1994; 50: 596–600.
73.
HeatonRK, CheluneGJ, TalleyJL, et al.. Wisconsin Card Sorting Test (WCST). Revised and expandedOdessa, FL: Psychological Assessment Resources, 1993.
74.
ValeFAC, Balieiro-JrAP and Silva-FilhoJH. Memory complaint scale (MCS). Proposed tool for active systematic search. Dement Neuropsychol2012; 6: 212–218.
75.
NortonDJ, AmariglioR, ProtasH, et al.. Subjective memory complaints in preclinical autosomal dominant Alzheimer disease. Neurology2017; 89: 1464–1470.
76.
GatchelJR, LoperaF, NortonDJ, et al.. Association of subjective cognitive decline with markers of brain pathology in preclinical autosomal dominant Alzheimer’s disease. J Neurol Neurosurg Psychiatry2020; 91: 330–332.
77.
FolsteinMF, FolsteinSE and McHughPR. Mini-Mental State Examination (MMS, MMSE). APA PsycTests, 1975.
78.
Guzmán-VélezE, MartínezJ, PappK, et al.. Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers. Neurology2020; 95: e1312–e1321.
79.
QuirozYT, AllyBA, CeloneK, et al.. Event-related potential markers of brain changes in preclinical familial Alzheimer disease. Neurology2011; 77: 469–475.
80.
AyutyanontN, LangbaumJBS, HendrixSB, et al.. The Alzheimer’s Prevention Initiative Composite Cognitive Test Score: sample size estimates for the evaluation of preclinical Alzheimer’s disease treatments in presenilin 1 E280A mutation carriers. J Clin Psychiatry2014; 75: 652–660.
81.
LemereCA, LoperaF, KosikKS, et al.. The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat Med1996; 2: 1146–1150.
82.
Velez-PardoC, ArellanoJI, Cardona-GomezP, et al.. CA1 hippocampal neuronal loss in familial Alzheimer’s disease presenilin-1 E280A mutation is related to epilepsy. Epilepsia2004; 45: 751–756.
83.
QuirozYT, SperlingRA, NortonDJ, et al.. Association between amyloid and tau accumulation in young adults with autosomal dominant Alzheimer disease. JAMA Neurol2018; 75: 548–556.
84.
SilverbergNB, RyanLM, CarrilloMC, et al.. Assessment of cognition in early dementia. Alzheimers Dement2011; 7: e60–e76.
85.
MedinaLD, WooE, Rodriguez-AgudeloY, et al.. Reaction time and response inhibition in autosomal dominant Alzheimer’s disease. Brain Cogn2021; 147: 105656.
86.
MindtMR, ByrdD, SaezP, et al.. Increasing culturally competent neuropsychological services for ethnic minority populations: a call to action. Clin Neuropsychol2010; 24: 429–453.
87.
ParraMA, AbrahamsS, LogieRH, et al.. Visual short-term memory binding deficits in familial Alzheimer’s disease. Brain2010; 133: 2702–2713.
88.
TiradoV, MuñozC, AguirreC, et al.. Performance of carriers and non-carriers of the E280A mutation for familial Alzheimer’s disease in a naming test. Rev Neurol2004; 39: 322–326.
89.
Vila-CastelarC, Guzmán-VélezE, Pardilla-DelgadoE, et al.. Examining sex differences in markers of cognition and neurodegeneration in autosomal dominant Alzheimer’s disease: preliminary findings from the Colombian Alzheimer’s Prevention Initiative Biomarker Study. J Alzheimers Dis2020; 77: 1743–1753.
